HIMS - Hims & Hers Health: Expecting A Healthy Report

2024-07-21 10:00:00 ET

Summary

• Hims & Hers Health has fallen below $20 after initial excitement over a compounded GLP-1 drug solution wanes.
• The health and wellness platform offers a compounded semaglutide drug at lower prices due to shortage of name-brand drugs.
• A short report from Hunterbrook Media questioned the business practices, but the investment story isn't based on the GLP-1 drug compound.
• After the recent dip, HIMS stock is cheap at only ~2.5x '25 sales targets.

Hims & Hers Health ( HIMS ) has slipped back down below $20 after the initial excitement over access to a GLP-1 drug solution has worn off. The online health and wellness company was hit with another short report, but the stock mostly shook off the issues addressed by the attack. My investment thesis remains Bullish on the stock over the long term, with the current price providing a good entry point as the GLP-1 compounded drugs should provide a sales boost....

For further details see: